Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Atara Biotherapeutics Inc    ATRA

ATARA BIOTHERAPEUTICS INC (ATRA)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/09/2018 10/10/2018 10/11/2018 10/12/2018 10/15/2018 Date
36.92(c) 35.53(c) 35.54(c) 36.42(c) 35.57 Last
690 847 562 590 329 944 389 844 419 067 Volume
-1.91% -3.76% +0.03% +2.48% -2.33% Change
More quotes
Financials (USD)
Sales 2018 -
EBIT 2018 -201 M
Net income 2018 -194 M
Finance 2018 183 M
Yield 2018 -
Sales 2019 0,83 M
EBIT 2019 -236 M
Net income 2019 -225 M
Finance 2019 51,8 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 1 928x
Capitalization 1 651 M
More Financials
Company
Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology.Its product candidates are biologics targeting myostatin and activin, members of the... 
More about the company
Surperformance© ratings of Atara Biotherapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ATARA BIOTHERAPEUTICS INC
09/25ATARA BIOTHERAPEUTICS : Reports Inducement Grants Under Nasdaq Listing Rule 5635..
AQ
09/24ATARA BIOTHERAPEUTICS : Reports Inducement Grants Under Nasdaq Listing Rule 5635..
AQ
09/12ATARA BIOTHERAPEUTICS : Appoints Cancer Research and Clinical Development Vetera..
AQ
09/12ATARA BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-..
AQ
09/11Atara Biotherapeutics Appoints Cancer Research and Clinical Development Veter..
GL
09/07ATARA BIOTHERAPEUTICS : and Moffitt Cancer Center Announce Strategic Collaborati..
AQ
09/06Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaborat..
GL
09/01ATARA BIOTHERAPEUTICS : to Participate at Two Upcoming Conferences
AQ
08/31Atara Biotherapeutics to Participate at Two Upcoming Conferences
GL
08/07ATARA BIOTHERAPEUTICS : Reports Inducement Grants Under Nasdaq Listing Rule 5635..
AQ
More news
Sector news : Bio Therapeutic Drugs
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
10/02GILEAD SCIENCES : Allogene Sets IPO at 16 Million Shares; Sees Pricing $16-$18
DJ
09/28FDA Approves Libtayo to Treat Advanced Cutaneous Squamous Cell Carcinoma
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/14Atara Biotherapeutics Inc $ATRA Given Average Recommendation of “Hold” by Bro.. 
10/11Investors Purchase Large Volume of Call Options on Atara Biotherapeutics $ATR.. 
10/10Atara Biotherapeutics $ATRA Trading Down 7.1% Following Insider Selling  
10/08Want automatic email alerts for $ATRA $OESX $CNXN $ST $CIB? Subscribe to Mark.. 
10/08Atara Biotherapeutics Inc $ATRA CEO Sells $313,716.00 in Stock  
More tweets
Qtime:56
News from SeekingAlpha
10/08ATARA : Forecasting The Upcoming Clinical Binary Of Tab-Cel 
09/06Atara Biotherapeutics (ATRA) Presents At 4th Annual CAR-TCR Summit 2018 - Sli.. 
09/06Atara Biotherapeutics and Moffitt Cancer Center collaborates to develop next-.. 
08/30Pfizer mid-stage flop with domagrozumab in DMD another setback for myostatin .. 
08/16BULLETPROOF INVESTING PERFORMANCE UP : Week 38 
Chart ATARA BIOTHERAPEUTICS INC
Duration : Period :
Atara Biotherapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ATARA BIOTHERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 43,5 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Issac E. Ciechanover Chairman, President & Chief Executive Officer
Utpal Koppikar Chief Financial Officer
Christopher M. Haqq Chief Scientific Officer, Executive VP-R&D
Joe Newell Chief Technical Operations Officer & Executive VP
Kanya Rajangam Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ATARA BIOTHERAPEUTICS INC101.22%1 611
GILEAD SCIENCES2.72%93 985
VERTEX PHARMACEUTICALS20.99%44 892
REGENERON PHARMACEUTICALS2.18%39 451
NEUROCRINE BIOSCIENCES, INC.43.68%9 776
GENMAB-10.38%8 786